Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5–10% and >10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several European registries have since validated the ESC/ERS risk status model; however, it is unknown if the ESC/ERS tool predicts clinical worsening or hospitalizations.(288)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [288]
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationMacitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationSelexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Self-citationBenza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R. P., Foreman, A. J., Badesch, D. B., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-0676 · Cited by 557
Kylhammar, D., Kjellström, B., Hjalmarsson, C., Jansson, K., Nisell, M., Söderberg, S., Wikström, G., & Rådegran, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx257 · Cited by 540
Hoeper, M. M., Huscher, D., Ghofrani, H. A., Delcroix, M., Distler, O., Schweiger, C., Grunig, E., Staehler, G., Rosenkranz, S., Halank, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.026 · Cited by 466
Self-citationUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Cited by
Items 201–300 of 739
Lung transplantation for pulmonary hypertension
Hwalek, A. E., Rosenheck, J. P., & Whitson, B. A. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-2021-20 · Cited by 21
“Risk stratification using validated criteria guides initial therapies and defines risk for mortality (12,14,15).”
Does Pulmonary Artery Pulsatility Index Predict Mortality in Pulmonary Arterial Hypertension?
Lim, Y., Low, T. T., Chan, S. P., Lin, W., Teo, T. W., Jang, J. J., Kuntjoro, I., Tay, E. L., & Yip, J. W.-L. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13450 · Cited by 21
Sugiyama, Y., Matsubara, H., Shimokawahara, H., & Ogawa, A. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.04.003 · Cited by 21
Badagliacca, R., Vizza, C. D., Lang, I. M., Sadushi‐Kolici, R., Papa, S., Manzi, G., Filomena, D., Ogawa, A., Shimokawahara, H., & Matsubara, H. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107099 · Cited by 21
Self-citationReal-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE
Muller, A., Subías, P. E., Fernandes, C., Fontana, M., Lange, T. J., Söderberg, S., & Gaine, S. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02730-8 · Cited by 21
“Similar to contemporary disease registries [8, 20] using the three-strata risk assessment method (as recommended for incident patients in the current ESC/ERS guidelines) [1, 2], the majority of incident patients in EXPOSURE were in the intermediate risk group.”
MethodResultInfluentialEvaluation of pulmonary hypertension by right heart catheterisation: does timing matter?
Yogeswaran, A., Richter, M. J., Sommer, N., Ghofrani, H. A., Seeger, W., Gall, H. J., & Tello, K. (2020) · European Respiratory Journal · doi:10.1183/13993003.01892-2019 · Cited by 21
Self-citationIntegrating haemodynamics identifies an extreme pulmonary hypertension phenotype
Oldham, W. M., Hess, E., Waldo, S. W., Humbert, M. J. C., Choudhary, G., & Maron, B. A. (2021) · European Respiratory Journal · doi:10.1183/13993003.04625-2020 · Cited by 21
Dean, B. B., Saundankar, V., Stafkey-Mailey, D., Anguiano, R. H., Nelsen, A. C., Gordon, K., & Classi, P. M. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00183-x · Cited by 21
Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension
Zelt, J. G. E., Hossain, A., Sun, L. Y., Mehta, S., Chandy, G., Davies, R. A., Contreras-Domínguez, V., Dunne, R., Doyle-Cox, C., Wells, G. A., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.026 · Cited by 21
Prognostic value of cardiopulmonary exercise testing in pulmonary arterial hypertension
Baccelli, A., Rinaldo, R. F., Haji, G., Davies, R. J., Giudice, F. L., Gin‐Sing, W., Vigo, B., Centanni, S., Gibbs, J. S. R., & Howard, L. (2025) · European Respiratory Journal · doi:10.1183/13993003.02026-2024 · Cited by 20
Self-citationSahay, S., Visovatti, S., Tonelli, A. R., Villasmil, N., Austin, E. D., Badagliacca, R., Berger, R. M. F., Boucly, A., Chen, Y., Church, C., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.04.015 · Cited by 20
Self-citationSouza, R., Delcroix, M., Galiè, N., Jansa, P., Mehta, S., Pulido, T., Rubin, L. J., Sastry, B. K. S., Simonneau, G., Sitbon, O., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02199-x · Cited by 20
“Generally, long-term outcome data on PAH patients are limited [1, 2, 16].”
BackgroundSelf-citationRosenkranz, S. (2023) · Herz · doi:10.1007/s00059-022-05155-1 · Cited by 20
Self-citationAhmed, A., Ahmed, S., Kempe, D., & Rådegran, G. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead012 · Cited by 20
“Our results confirm these revised estimates for 1-year mortality in PAH, adding further evidence to previous studies displaying similar findings.(16,17) Notably, in our study, patients were included from early 2000s, which may have influenced survival, as treatment strategies have evolved.”
MethodResultSahay, S., Villasmil, N., Wang, F., Wooten, M., Nguyen, D. T., Fauvel, C., Benza, R. L., & Graviss, E. A. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.02.052 · Cited by 20
Dardi, F., Guarino, D., Ballerini, A., Bertozzi, R., Donato, F., Cennerazzo, F., Salvi, M., Nardi, E., Magnani, I., Manes, A., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00225-2024 · Cited by 20
“…risk table derived tools: Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) three-strata (1.0) [23] and four-strata (2.0) [22, 24] risk tools, French Pulmonary Hypertension Registry (FPHR) invasive risk assessment strategy [25] and the…”
MethodInfluentialGlobal Burden of Pulmonary Arterial Hypertension and Associated Heart Failure
Huang, H., Hu, C., Zhang, R., Xu, H., Cao, M., & Fu, Y. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.12.005 · Cited by 20
Right Atrial Pressure During Exercise Predicts Survival in Patients With Pulmonary Hypertension
Lichtblau, M., Bader, P. R., Saxer, S., Berlier, C., Schwarz, E. I., Hasler, E., Furian, M., Grünig, E., Bloch, K. E., & Ulrich, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018123 · Cited by 20
Self-citationZhou, J., Chou, O. H. I., Wong, K. H. G., Lee, S., Leung, K. S. K., Liu, T., Cheung, B. M. Y., Wong, I. C. K., Tse, G., & Zhang, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.735906 · Cited by 20
“However, the model requires extensive clinical investigations, such as echocardiography and cardiopulmonary exercise testing (7).”
MethodDiagnosis and management of pulmonary arterial hypertension
Cullivan, S., Higgins, M., & Gaine, S. (2022) · Breathe · doi:10.1183/20734735.0168-2022 · Cited by 19
Longitudinal Changes in Risk Status in Pulmonary Arterial Hypertension
Bouzina, H., Rådegran, G., Butler, O., Hesselstrand, R., Hjalmarsson, C., Holl, K., Jansson, K., Klok, R. M., Söderberg, S., & Kjellström, B. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13162 · Cited by 19
Utilization of risk assessment tools in management of PAH: A PAH provider survey
Sahay, S., Balasubramanian, V. P., Memon, H. A., Poms, A. D., Bossone, E., Highland, K., Kay, D., Levine, D. J., Mullin, C. J., Melendres-Groves, L. D., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12057 · Cited by 19
Tseng, V., Collum, S. D., Allawzi, A. M., Crotty, K. M., Yeligar, S. M., Trammell, A. W., Smith, M. R., Kang, B., Sutliff, R. L., Ingram, J. L., et al. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.06.001 · Cited by 19
“Clinical outcomes in PH remain unacceptably poor, with median survival of only 3 years from time of diagnosis [1].”
BackgroundFrost, A., Hoeper, M. M., Barberà, J. A., Vachiéry, J., Blair, C. J., Langley, J., & Rubin, L. J. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.001 · Cited by 19
Self-citationImoto, K., Okada, M., & Yamawaki, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010062 · Cited by 19
White, R. J., Noordegraaf, A. V., Rosenkranz, S., Oudiz, R. J., McLaughlin, V. V., Hoeper, M. M., Grünig, E., Ghofrani, H. A., Chakinala, M. M., Barberà, J. A., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1180-1 · Cited by 19
Self-citationBatool, M., Berghausen, E. M., Zierden, M., Vantler, M., SCHERMULY, R. T., Baldus, S. E., Rosenkranz, S., & ten Freyhaus, H. (2020) · Basic Research in Cardiology · doi:10.1007/s00395-020-00826-8 · Cited by 19
Self-citationRisk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review
Lokhorst, C., van der Werf, S., Berger, R. M. F., & Douwes, J. M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1035453 · Cited by 18
Celant, L. R., Wessels, J. N., Marcus, J. T., Meijboom, L. J., Bogaard, H. J., de Man, F. S., & Noordegraaf, A. V. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.07.028 · Cited by 18
Pienn, M., Gertz, R. J., Gerhardt, F., Kröger, J. R., Zaytoun, H., Reimer, R. P., Kaplan, A., Wißmüller, M., Kovács, G., Rosenkranz, S., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.08.013 · Cited by 18
Self-citationBouzina, H., & Rådegran, G. (2020) · Pulmonary Circulation · doi:10.1177/2045894020931317 · Cited by 18
Perioperative Management of Pulmonary Hypertension. A Review
Wood, C., Balčiūnas, M., Lordan, J. L., & Mellor, A. J. (2021) · The Journal of Critical Care Medicine · doi:10.2478/jccm-2021-0007 · Cited by 19
“Risk score stratification tools highlight the disease trajectory from registry outcomes, which includes both European and United States registry data (United Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)) [57,58].”
Wang, W., Jiang, Z., Zhang, D., Fu, L., Wan, R., & Hong, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672159 · Cited by 18
Scott, T., Qin, C. X., Drummond, G. R., Hobbs, A. J., & Kemp‐Harper, B. K. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.14525 · Cited by 18
“(2) The activation step is initiated when further DAMPs are detected by NLRP3.”
BackgroundCarbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension
Diamanti, E., Karava, V., Yerly, P., & Aubert, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010132 · Cited by 18
“The six parameters including functional class NYHA, 6-minwalk-test (MWT) distance, NT-proBNP, RAP, CI, and SvO2 were graded for each patient from 1 to 3 (1: low-risk; 2: intermediate-risk; 3: high-risk) according to the proposed cut-off values [21].”
BackgroundLai, J., Zhao, J., Li, K., Qin, X., Wang, H., Tian, Z., Wang, Q., Li, M., Guo, X., Liu, Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.872795 · Cited by 18
Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography
Mercurio, V., Hassan, H. J., Naranjo, M., Cuomo, A., Mazurek, J. A., Forfia, P. R., Balasubramanian, A., Simpson, C. E., Damico, R. L., Kolb, T. M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144034 · Cited by 18
“These were used for the risk stratification of patients and included: World Health Organization functional class (WHO FC), six-minute walking distance (6MWD), serum brain natriuretic peptide (BNP) or Nterminal prohormone BNP (NT-proBNP), and RHC-derived right atrial pressure (RAP) and cardiac index (CI) [6].”
BackgroundMethodInfluentialIntegrating epigenetics and metabolomics to advance treatments for pulmonary arterial hypertension
Ranasinghe, A. D. C. U., & Schwarz, M. A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115245 · Cited by 18
Xiong, W. G., Zhao, Y., Xu, M., Pudasaini, B., Guo, X., & Liu, J. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0712-7 · Cited by 18
“validated the validity of risk assessment strategy in 2015 European PH guidelines with a model composed of WHO FC, 6MWD, BNP or NT-pro BNP, right atrial pressure, cardiac index and mixed venous oxygen saturation [25].”
MethodPrognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension
Suzuki, S., Asano, R., Aoki, T., Nakayama, S., Ueda, J., Tsuji, A., Noguchi, T., & Ogo, T. (2022) · Open Heart · doi:10.1136/openhrt-2022-002054 · Cited by 17
Epidemiology of PAH in Korea: An Analysis of the National Health Insurance Data, 2002–2018
Jang, A. Y., Lee, H., Lee, H., Kim, H. C., & Chung, W. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2022.0231 · Cited by 17
Selexipag in the management of pulmonary arterial hypertension: an update
Coghlan, G., Picken, C., & Clapp, L. H. (2019) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s181313 · Cited by 17
“6-year survival among IPAH patients was reported.(15) In the UK national registry, average survival is less than 4 years for IPAH,(16) for reasons that have yet to be determined.”
BackgroundInfluentialInflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances
Mercurio, V., Cuomo, A., Naranjo, M., & Hassoun, P. M. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200025 · Cited by 17
Wißmüller, M., Xanthouli, P., Benjamin, N., Grünig, E., Richter, M. J., Gall, H. J., Ghofrani, H. A., Herkenrath, S. D., Skowasch, D., Pizarro, C., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13804 · Cited by 17
“The mean grade was rounded off to the nearest integer, which was used to define the patient’s risk group.(16,17)”
MethodSelf-citationSpießhoefer, J., Herkenrath, S. D., Möhr, M., Randerath, W. J., Tuleta, I., Diller, G., Emdin, M., Young, P., Henke, C., Florian, A. R., et al. (2019) · Bioscience Reports · doi:10.1042/bsr20190392 · Cited by 17
Ashraf, H., & Rosenthal, J. (2020) · Cardiology Clinics · doi:10.1016/j.ccl.2020.01.008 · Cited by 17
Systemic sclerosis-associated pulmonary arterial hypertension in children
Apitz, C., & Girschick, H. J. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-901 · Cited by 17
Echocardiographic Parameters and Risk Prediction in Pulmonary Arterial Hypertension
Mukherjee, M., Jani, V., Osgueritchian, R., Mombeini, H., Abidov, A. A., Beck, G. J., ERZURUM, S. C., Frantz, R. P., Hassoun, P. M., Hemnes, A. R., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.04.007 · Cited by 16
Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
Jansa, P., Ambrož, D., Kuhn, M., Dytrych, V., Aschermann, M., Černý, V., Gressin, V., Heller, S., Kunstýř, J., Širanec, M., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12038 · Cited by 16
Göransson, C., Vejlstrup, N. G., & Carlsen, J. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.01.1305 · Cited by 16
Nagel, C., Benjamin, N., Egenlauf, B., Eichstaedt, C. A., Fischer, C., Palevičiūtė, E., Čelutkienė, J., Harutyunova, S., Mayer, E., Nasereddin, M., et al. (2021) · Respiration · doi:10.1159/000512316 · Cited by 16
Self-citationRefined risk stratification in pulmonary arterial hypertension and timing of lung transplantation
Olsson, K. M., Richter, M. J., Kamp, J. C., Gall, H. J., Ghofrani, H. A., Fuge, J., Ewert, R., & Hoeper, M. M. (2022) · European Respiratory Journal · doi:10.1183/13993003.03087-2021 · Cited by 16
Self-citationRisk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives
Vraka, A., Diamanti, E., Kularatne, M., Yerly, P., Lador, F., Aubert, J., & Lechartier, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134349 · Cited by 15
“The original COMPERA risk score and the abridged version of the REVEAL 2.0 risk score (REVEAL Lite 2) [73] are within the assessment tools with fewer parameters that are easily assessed in the outpatient clinic.”
BackgroundMethodInfluentialExploring the pathogenesis of pulmonary vascular disease
EJIKEME, C. P., & Safdar, Z. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1402639 · Cited by 15
Zhang, S., Li, S., Gao, L., Zhao, Q., Yang, T., Zeng, Q., Huang, Z., Li, X., Duan, A., Wang, Y., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02925-9 · Cited by 15
“An abbreviated ESC risk stratification strategy was used to categorize patients as low-, intermediate-, or high-risk [13].”
MethodPulmonary hypertension in pediatrics: from clinical suspicion to management
Wacker, J., & Beghetti, M. (2025) · European Journal of Pediatrics · doi:10.1007/s00431-025-06099-4 · Cited by 15
“…Early and Long-Term PAH Disease Management (REVEAL) 2.0 and 2.0 lite risk scores, the Comparative, Prospective Registry of Newly Initiated Therapies for pulmonary hypertension (COMPERA) risk score, or the newly introduced four-strata risk assessment tool in the 2022 ESC guidelines [1, 27–29].”
InfluentialPulmonary arterial hypertension: closing the gap in congenital heart disease
Brida, M., Nashat, H., & Gatzoulis, M. Α. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000695 · Cited by 15
Tonelli, A. R., Sahay, S., Gordon, K. W., Edwards, L. D., Allmon, A. G., Broderick, M. J., & Nelsen, A. C. (2020) · Pulmonary Circulation · doi:10.1177/2045894020977025 · Cited by 15
Dardi, F., Manes, A., Guarino, D., Zuffa, E., Lorenzis, A. D., Magnani, I., Rotunno, M., Ballerini, A., Russo, G. L., Nardi, E., et al. (2021) · Open Heart · doi:10.1136/openhrt-2021-001725 · Cited by 15
“14 15 14–16 The limitation of this approach in evaluating the individual risk profile is based on the arbitrary attribution of the same scores to all the variables and on the final average value, which may be the result of parameters from all risks groups; moreover it is not a simple tool to use at…”
Clinical application of risk assessment in PAH: Expert center APRN recommendations
Wilson, M. A., Keeley, J. H., Kingman, M. S., McDevitt, S., Brewer, J., Rogers, F., Hill, W., Rideman, Z., & Broderick, M. J. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12106 · Cited by 15
IMproving PULmonary hypertension Screening by Echocardiography: IMPULSE
Slegg, O., Willis, J., Wilkinson, F., Sparey, J., Wild, C. B., Rossdale, J., Ross, R. M., Pauling, J. D., Carson, K., Kandan, S. R., et al. (2022) · Echo Research and Practice · doi:10.1186/s44156-022-00010-9 · Cited by 15
“Early recognition and treatment are key in determining longterm prognosis [1].”
BackgroundKelly, N. J., & Chan, S. Y. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311378 · Cited by 15
“…the US-based REVEAL/REVEAL 2.0 [230,232] and the European-based Swedish Pulmonary Arterial Hypertension Register (SPAHR) [233], Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) [234], and French Pulmonary Hypertension Registry (FPHR) [235].”
Influential2022 Update of indications and contraindications for lung transplantation in France
Pavec, J. L., Pison, C. M., Hirschi, S., Bunel, V., Mordant, P., Brugière, O., Guen, M. L., Olland, A., Coiffard, B., Renaud-Picard, B., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100981 · Cited by 15
Kan, J., Zhang, H., Xie, D., Wei, Y., Zhang, J., Zhang, C., Yang, Z., Gu, H., Fan, F., Gu, H., et al. (2023) · EuroIntervention · doi:10.4244/eij-d-23-00349 · Cited by 14
Zhang, S., Gao, L., Zhao, Z., Zhao, Q., Yang, T., Zeng, Q., Zhang, Y., Li, X., Huang, Z., Duan, A., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107643 · Cited by 14
Sun, H., Du, Z., Zhang, X., Gao, S., Ji, Z., Luo, G., & Pan, S. (2024) · Respiratory Research · doi:10.1186/s12931-024-02813-2 · Cited by 14
“Autoantibodies and local lymphoid follicles are also involved in inflammation and immune activation in pulmonary hypertension [18, 19].”
BackgroundRisk stratification in patients with residual pulmonary hypertension after pulmonary endarterectomy
Ghio, S., Klersy, C., Corsico, A. G., Gamba, S. L., Monterosso, C., Masiglat, J., Borrelli, E., Scelsi, L., Greco, A., Piloni, D., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.04.003 · Cited by 14
Sung, S., Yeh, W., Chiang, C., Huang, C., Huang, W., Chen, C.-H., & Cheng, H. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01816-0 · Cited by 14
“In contrast, CI among the hemodynamic indices was suggested to be predictive of clinical outcomes in European cohorts of PAH [3, 35].”
BackgroundGugliandolo, E., Macrì, F., Fusco, R., Siracusa, R., Cordaro, M., D’Amico, R., Peritore, A. F., Impellizzeri, D., Genovese, T., Cuzzocrea, S., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106750 · Cited by 14
Skowasch, D., Klose, H. F. E., Ewert, R., Wilkens, H., Richter, M. J., Rosenkranz, S., Setzer, G., Grünig, E., & Halank, M. (2023) · ERJ Open Research · doi:10.1183/23120541.00668-2023 · Cited by 14
Self-citationPrognostic value of deep echocardiographic phenotyping in pulmonary arterial hypertension
Ghio, S., Badagliacca, R., Acquaro, M., Filomena, D., Recchioni, T., Papa, S., Colombo, D., Ditali, V., Carrozzi, C., Greco, A., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00587-2023 · Cited by 14
Self-citationGao, L., Zhang, S., Zhao, Z., Zhao, Q., Yang, T., Zeng, Q., Zhang, Y., Li, X., Huang, Z., Duan, A., et al. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s434720 · Cited by 14
“13,14 The exclusion criteria included the following: (1) existence of cancer, such as blood cancer and tumors; (2) presence of inflammatory conditions or ongoing infection; and (3) absence of data regarding neutrophil, monocyte, lymphocyte, and platelet counts.”
BackgroundRisk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it
Benza, R. L., Lohmueller, L. C., Kraisangka, J., & Kanwar, M. K. (2018) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-16.3.125 · Cited by 14
Bouzina, H., & Rådegran, G. (2018) · ERJ Open Research · doi:10.1183/23120541.00035-2018 · Cited by 14
Kjellström, B., Lindholm, A., & Ostenfeld, E. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00479-7 · Cited by 14
Prediction Models and Scores in Adult Congenital Heart Disease
Arvanitaki, A., Ntiloudi, D., Giannakoulas, G. A., & Dimopoulos, K. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827999210111181554 · Cited by 14
A novel approach to perioperative risk assessment for patients with pulmonary hypertension
Hassan, H. J., Housten, T., Balasubramanian, A., Simpson, C. E., Damico, R. L., Mathai, S. C., Hassoun, P. M., Steppan, J., Leary, P. J., & Kolb, T. M. (2021) · ERJ Open Research · doi:10.1183/23120541.00257-2021 · Cited by 15
Ahmed, A., Ahmed, S., & Rådegran, G. (2021) · Pulmonary Circulation · doi:10.1177/20458940211041500 · Cited by 14
Pulmonary arterial hypertension registries: past, present and into the future
Weatherald, J. C., Reis, A., Sitbon, O., & Humbert, M. J. C. (2019) · European Respiratory Review · doi:10.1183/16000617.0128-2019 · Cited by 14
Providing compassionate care in the ICU
Curtis, J. R., & Levy, M. M. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202112-2787ed · Cited by 13
Ahmed, S., Ahmed, A., & Rådegran, G. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100152 · Cited by 13
Advances in medical therapy for pulmonary arterial hypertension
Sisniega, C., Zayas, N., & Pulido, T. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000583 · Cited by 13
Pulmonary arterial hypertension: guidelines and unmet clinical needs
Giuggioli, D., Bruni, C., Cacciapaglia, F., Dardi, F., Cata, A. D., Papa, N. D., Iannone, F., Lunardi, C., Maglione, W., Molinaro, F., et al. (2021) · Reumatismo · doi:10.4081/reumatismo.2020.1310 · Cited by 13
Benza, R. L., Boucly, A., Farber, H. W., Frost, A., Ghofrani, H. A., Hoeper, M. M., Lambelet, M., Rahner, C., Bansilal, S., Nikkho, S. M., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.10.013 · Cited by 13
“5 mg-max three times a day (n = 231) Placebo (n = 109) Total (n = 396) Renal information Renal insufficiency 42 (18) 16 (15) 67 (17) No renal insufficiency 180 (78) 88 (81) 311 (79) Missing information 9 (4) 5 (5) 18 (5) WHO functional class I 5 (2) 3 (3) 12 (3) II 98 (42) 54 (50) 169 (43) III 128 (55) 49 (45) 212 (54…”
MethodSelf-citationThe Lung Transplant Candidate, Indications, Timing, and Selection Criteria
Mannem, H. C., Aversa, M. M., Keller, T., & Kapnadak, S. G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.001 · Cited by 13
Heart rate and risk of death among patients with Pulmonary Hypertension: A 12-lead ECG analysis
Bouchery-Bardet, H., Créveuil, C., Bauer, F., Beygui, F., Champ‐Rigot, L., Saloux, É., Labombarda, F., Roule, V., Sabatier, R., Legallois, D., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.09.008 · Cited by 13
Practical management of riociguat in patients with pulmonary arterial hypertension
Halank, M., Tausche, K., Grünig, E., Ewert, R., & Preston, I. R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619868938 · Cited by 13
Self-citationWong, A. K., & Channick, R. W. (2019) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s173050 · Cited by 13
“The prognosis for this condition remains guarded, with mortality 1 year after diagnosis as high as 21% in patients classified as highest risk.(4) Modifying this risk via various methods, including pharmacotherapy, has important implications for prognosis and survival in these patients.”
BackgroundLiu, B., Wu, W., Zeng, Q.-X., Liu, Z., Niu, L.-L., Tian, Y., Luo, Q., Zhao, Z., Quan, R., Lin, J., et al. (2019) · International journal of cardiac imaging · doi:10.1007/s10554-019-01743-1 · Cited by 13
Risk assessment in precapillary pulmonary hypertension: a comparative analysis
Sonnweber, T., Schneider, E.-M., Nairz, M., Theurl, I., Weiß, G., Tymoszuk, P., & Löffler‐Ragg, J. (2021) · Respiratory Research · doi:10.1186/s12931-021-01624-z · Cited by 13
“The latter is of high clinical relevance as the risk prediction significantly affects therapeutic decisions and scheduling of follow-up evaluations [4, 7, 9].”
BackgroundRisk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?
Farber, H. W., & Benza, R. L. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201801-0042ed · Cited by 13
Lokhorst, C., van der Werf, S., Berger, R. M. F., & Douwes, J. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034151 · Cited by 12
Bjørkekjær, H. J., Bruni, C., Broch, K., Brunborg, C., Carreira, P. E., Airò, P., Simeón‐Aznar, C. P., Truchetet, M., Giollo, A., Balbir‐Gurman, A., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf053 · Cited by 12
“Previous studies on risk stratification in SSc-PAH have often been limited to single-centre studies, subgroup analyses or focused on treatment-naïve patients using the 2015 haemodynamic criteria [12, 21–28 , 41–”
InfluentialSelf-citationKörperliches Training bei pulmonaler Hypertonie – ein systematisches Review mit Metaanalyse
Glöckl, R., Schneeberger, T., Boeselt, T., Kenn, K., Koczulla, A. R., Held, M., Oberhoffer, R., & Halle, M. (2019) · Pneumologie · doi:10.1055/a-1005-8678 · Cited by 12
Maarman, G. J. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00484.2021 · Cited by 12
Arvanitaki, A., Vrana, E., Boutsikou, M., Anthi, A., Apostolopoulou, S. C., Avgeropoulou, A., Demerouti, E., Patrianakos, A. P., Karyofyllis, P., Mitrouska, I., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12086 · Cited by 12
“For each patient, the sum of all grades was divided by the number of available variables and rounded to the next integer to define the risk group.(9,10)”
MethodSpilimbergo, F. B., Rodrigues, R. P., Dias‐Pinto, M. C., Blanco, D. C., Barbieri, G. M., Andrade‐Lima, M., Fagundes, A. L., Gazzana, M. B., Roncato, G., Mello, M. M., et al. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12193 · Cited by 12
Zhang, J., Kan, J., Wei, Y., Zhang, C., Yang, Z., Gu, H., Fan, F., Gu, H., Wang, Q., Xie, D., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.03.015 · Cited by 12
Benza, R. L., Adamson, P. B., Bhatt, D. L., Frick, F., Olsson, G., Bergh, N., & Dahlöf, B. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12323 · Cited by 12
“It has been shown that PAH patients who maintain a low ‐ risk status after initial treatment fare better than those who fall into the intermediate ‐ and high ‐ risk categories 14,60,61 TABLE 3 (Continued) also represents a valuable assessment of clinical worsening or improvement.”
BackgroundPrognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension
Zhang, Z., Liu, C., Ma, J., Ma, J.-S., Wang, J., Li, R., Lu, D., Zhou, Y., Lian, T., Zhang, S.-J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.077 · Cited by 12
Metadata
- Authors
- Hoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., Distler, O., Opitz, C., Gibbs, J. S. R., Delcroix, M., Ghofrani, H. A., Huscher, D., Pittrow, D., Rosenkranz, S., & Grünig, E.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Cologne (DE)
- University Hospital Heidelberg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Sapienza University of Rome (IT)
- University Hospital Zurich (CH)
- DRK Kliniken Berlin (DE)
- Imperial College London (GB)
- Universitair Ziekenhuis Leuven (BE)
- Justus-Liebig-Universität Gießen (DE)
- Technische Universität Dresden (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1700740
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2743897368
- Cited by
- 660
- References
- 21
- Citations by year
- 2026: 21 · 2025: 52 · 2024: 74 · 2023: 84 · 2022: 101 · 2021: 111 · 2020: 92 · 2019: 63 · 2018: 53 · 2017: 8
- FWCI
- 48.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- GlaxoSmithKline
- German Centre of Lung Research
- Bayer
- Actelion Pharmaceuticals
- Deutsche Forschungsgemeinschaft (HO 1599/2-1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, mortality prediction, risk stratification, one-year mortality, functional class, 6-minute walk distance, brain natriuretic peptide, right atrial pressure, cardiac index, mixed venous oxygen saturation
- MeSH terms
- Walk Test, Adult, Aged, Aged, 80 and over, Europe, Female, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prospective Studies, Registries, Severity of Illness Index, Practice Guidelines as Topic, Risk Assessment, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.